Brad Herskowitz, MD

Brad Herskowitz, MD is a board-certified neurologist with just over 20 years of medical experience. He practices general neurology at The Neurology Group, a cutting-edge, research-driven medical practice in Miami that serves patients from communities across southeastern Florida.

Dr. Brad J. Herskowitz has special training in comprehensive stroke and Alzheimer's Disease, concussion treatment, sleep disorder management, and migraine therapy. He’s also an expert in Botox® injection therapy for both cosmetic and neurological conditions.

Dr. Herskowitz has been a principal investigator in numerous clinical research trials, given many lectures on a wide range of topics in neurology, and published articles in several medical journals. He previously served as a Florida boxing ringside physician and is currently a team physician for the Miami Heat NBA basketball team. He’s also the Clinical Assistant Professor for the Department of Neurology at Florida International University Medical School.

After receiving his undergraduate degree from the University of Florida, Dr. Herskowitz obtained his medical degree from the University of Miami School of Medicine. He completed a two-year internal medicine residency at the University of Miami-Jackson Memorial Hospital before going on to complete a three-year neurology residency at Yale-New Haven Hospital, where he was chief resident.

Dr. Herskowitz a member of the American Academy of Neurology, the American Medical Association, and the American Society for Professional Ringside Physicians.

In addition to his office practice at The Neurology Group, Dr. Herskowitz is on staff at Baptist Health, West Kendall, Baptist South Miami Hospital, and Jackson South.

Professional Experience
January 2019 – Present   Neurologist, Botox Expert Injector- Chronic Migraines
May 2018 – Present   Neurologist, Clinical Trials of Florida, LLC.
May 2016 – Present   Neurologist, The Neurology Research Group, LLC., CEO
August 2017 – Present   Associate Clinical Professor - Florida International University, Herbert Wertheim College of Medicine
August 2012 – Present   Stroke Director, West Gables Rehabilitation Hospital
November 2007 – Present   Treating Neurologist, St. Anne’s Nursing Center & Residence, Miami, FL
March 2002 – Present   Investigator in Clinical Trials
May 2001 – Present   Partner with Neuroscience Consultants, LLC
August 2001 – Present   Miami Cardiovascular Institute (MCVI), Affiliated Researcher in Vascular Neurology
August 2004 – 2007   Boxing Ringside Physician
January 2004 – 2007   Director EEG Lab, Baptist Hospital of Miami
July 2003 – June 2004   Medical Director of Galloway Therapy Service, Outpatient Therapy Service

Publications
Herskowitz, A., Herskowitz, B.: “Treatment for Neck and Shoulder Pain with Botulinum Neurotoxins” Pain Practice (4).15, March 2004
Herskowitz, A., Herskowitz, B.: “Acute Paraparesis Due to Terbutaline Sulfate” Southern Medical Journal, February 2002; Volume 75, No. 2; pgs. 275-276
Lichstein, D., Herskowitz, B.” “Massive Gastrointestinal Bleeding from Meckel’s Diverticulum in a 91-year-old man”. Southern Medical Journal, August 1998; Volume 91, pgs. 753-754.
Jimenez, J., Herskowitz, B., Yunis, A.: “Pattern of Chemotherapy Induced Alopecia in a Young Rat Model”. Department of Hematology, August 1995 thru March 1996. National Hematology Conference
Herskowitz, B., Herskowitz, A., Braun, I.: “Cerebral Vasculitis and Infarction Associated with Chronic Use of Oxymetazoline Nasal Spray”. Submitted for Publication.

Research Experience
Sponsored Research as Sub-Investigator:
*-Indicates as Principal Investigator

2020
*T3D Therapeutics, Inc., A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D- 959 in Subjects with Mild-to-Moderate Alzheimer’s Disease.

2019
*Aptinyx, Inc. A Phase II Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment Associated With Parkinson's Disease.

*AriBio Co., Ltd. A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients with Mild to Moderate Alzheimer’s Disease.

*Longeveron, LLC. A Phase I, Prospective, Randomized, Double-Blinded, Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Longeveron Allogeneic Human Mesenchymal Stem Cell (LMSC) Infusion Versus Placebo in Patients with Alzheimer’s Disease.

SK Life Science, Inc., A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures.

SAGE Therapeutics, A Phase I, Double-Blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAGE-324 Oral Solution and to Assess the Relative Bioavailability of SAGE-324 Oral Suspension in Healthy Subjects with a Separate Open-label Part to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAGE-324 Oral Suspension in Subjects with Essential Tremor.

2018
*ADAMAS Pharmaceuticals Inc., A 3-Arm, Multicenter, Double-Clind, Placebo-Controlled, Randomized Study to Assess the Efficacy and Safety of ADS-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients with Walking Impairment

*Actinogen Medical, XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of Xanamem in Subjects with Mild Dementia due to Alzheimer’s Disease (AD)

2017
Sunovion Pharmaceuticals Inc., Efficacy and Safety of Eslicarbazepine Acetate as First Add-on to Levetiracetam or Lamotrigine Monotherapy or as Later Adjunctive Treatment for Subjects with Uncontrolled Partial-onset Seizures: A Multicenter Open-label, Non-randomized Trial.

2016
*AZTherapies, Inc.: A Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects with Evidence of Early Alzheimer’s Disease. (Protocol No.: AZT-001)

*AVANIR PHARMACEUTICALS INC., A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deuterated [d6]-dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type.

*Techfields, Inc., A Phase 2, multicenter, randomized, double-blind (within dose), placebo-controlled, parallel-group, dose-range-finding study to evaluate the efficacy and safety of TF0023 spray versus placebo in functional improvement of patients with ischemic strokes.

*Eli Lilly and Company, Protocol I7X-MC-LLCF(a) Effect of LY3202626 on Alzheimer’s Disease Progression as Measured by Cerebral 18F-AV-1451 Tau-PET in Mild Alzheimer’s Disease Dementia.

*Eli Lilly and Company, Protocol H8A-US-B004 Longitudinal Cohort Study of Resource use and Cost of Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s Disease in the United States (GERAS-US).

2012
*Pfizer.: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab(AAB-001, ELN 115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoproten E E4 Non-carriers [PAREXEL #204493].

2009
JANSSEN Alzheimer Immunotherapy: A Phase 3 Extension, Multicenter, Double-Blind, Long Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects with Alzheimer’s disease who Participated in Study ELN115727-301 or in Study ELN115727-302. (Protocol No.:ELN115727-351) CRO: PRA International

Pfizer Inc.: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Tanezumab on Peripheral Nerve Function in Patients with Osteoarthritis. (A4091026)

Sepracor Inc.: Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects with Partial Epilepsy Not Well Controlled By Current Antiepileptic Drugs. (Protocol No.: 093-045) CRO: Inc Research.

Supernus Pharmaceuticals Inc.: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Three-Arm, Parallel Group to Evaluate the Efficacy and Safety of Oxcarbazepine Extended-Release (OXC XR) (1200 and 2400mg/day) as Adjuntive Therapy in Subjects with Refractory Partial Seizures due to Epilepsy on up to Two Concomitant Antiepileptic Medications. (Protocol No.: 804P301) CRO: PAREXEL

Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR) as Adjunctive Therapy in Subjects with Refractory Partial Epilepsy on up to Two Concomitant Antiepileptic Medications. (Protocol No.: 804P302) CRO: PAREXEL

2008
Eisai Inc. and Pfizer Inc.: A 12-week, Multicenter, open label study to evaluate the effectiveness and safety of donepezil hydrochloride (E2020) in subjects with mild to severe Alzheimer’s disease residing in an assisted living facility. (Protocol No.: E2020-A001-415) CRO: PAREXEL International.

Elan Pharmaceutical Inc.: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of Bapineuzumab (AAB 001, ELN115727) in Patients with Mild to Moderate Alzheimer’s Disease who are Apolipoprotein E 4 Non-Carries. (Protocol No.: ELN115727-301) CRO: PRA International.

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of Bapineuzumab (AAB 001, ELN115727) in Patients with Mild to Moderate Alzheimer’s Disease who are Apolipoprotein E 4 Carries. (Protocol No.: ELN115727-302) CRO: PRA International.

Pfizer Inc.: A Phase 3, Multi-Center, Randomized, Double-Blind, Controlled Study of the Long-Term Analgesic Efficacy and Safety of Tanezumab Alone or in Combination with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs Alone in Patients with Osteoarthritis of the Knee or Hip. (Protocol No.: A4091025) CRO: PharmaNet, LLC.

2007
Johnson & Johnson: A Randomized – Withdrawal Phase III Study Evaluating the Safety and Efficacy of CG5503 Extended Release (ER) in Subjects with Painful Peripheral Neuropathy (DPN). Protocol No.: R331333-PAI-3015. CRO: INC Research.

*UCB Pharma Inc.: A Multicenter, Double-Blind, Historical Control Randomized Conversion to Monotherapy with Keppra XR for Treatment of Partial Onset Seizures Study. (Protocol No.: N01280) CRO: PRA International.

An Open-Label, Long Term Follow-Up Study with Keppra XR for Treatment of Partial Onset Seizures. (Protocol No.: N01281) CRO: PRA International.

*Biogen Idec: A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects with Relapsing Remitting Multiple Sclerosis. (Protocol No.: 109MS302) CRO: PRA International.

Minster Research LTD.: Multi-Centre, Parallel Group, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache and Open-Label Extension. (Protocol No.: TON/03/07-CLIN) CRO: PRA International.

Bayer Healthcare Pharmaceutical: Success of Titration, Analgesics. And B.E.T.A. Nurse Support on Acceptance Rates in Early MS Treatment with Betaseron (START) with Betaseron Study): An Open-Label, Multicenter,

Observational, Phase IV Study to Evaluate the Adherence to Treatment with 250mg (8MIU) IFNb-1b (Betaseron) Given Subcutaneous Every Other Day Over a period of up to 12 Months in Patients with a First Clinical Demyelinating Event Suggestive of Multiple Sclerosis (RRMS) Within the past 12 months. (Protocol No.: 311501) CRO: INC Research.

2006
*GlaxoSmithKline: A 28 day, Polysomnographic and Subject Assessments of GW679769, 10 and 30mg, for the Treatment of Primary Insomnia: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial (Protocol No.: MAD103894) CRO: PPD, Inc.

2005
Fujisawa Healthcare Inc.: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase II Study to Evaluate the Safety and Efficacy of FK 962 in Subjects with Mild to Moderate Alzheimer’s Disease (Protocol No.: 03-0-189) CRO: i3 Research

Bristol-Myers Squibb: A Pilot Study to examine the effects of Clopidogrel compared to Placebo on markers of inflammation in subjects with Metabolic Syndrome who are receiving background therapy including low dose aspirin (Protocol No.: L 9842)

Allergan: A Multicenter Study Evaluating the Efficacy and Safety of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex as Headache Prophylaxis in Migraine Patient with 15 or more Headaches per 4-Week Period in a 24-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase Followed by a 32-Week Open-Label Extension Phase. (Protocol No.:191622-079)

Wyeth Pharmaceuticals Inc.: A 3-Month, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Safety Tolerability, and Efficacy Study of 3 Does of Lecozotan (SRA-333) SR in Outpatients with Mild to Moderate Alzheimer’s Disease with Donepezil as Active Control (Protocol No.: 3098B1-201-WW)

A Multicenter, Randomized, Double-Blind, Long-Term Extension Study to Determine the Safety, Tolerability, and Preliminary Long Term Efficacy of Lecozotan (SRA-333) SR in Patients with Mild to Moderate Alzheimer’s Disease (Protocol No.: 3098B1-202-WW)

A 6-Month, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Saftey, Tolerability, and Efficacy Study of 3 Doses of Lecozotan (SRA-333) SR in Outpatients with Mile do Moderate Alzheimer’s Disease Treated with Cholinesterase Inhibitor (Protocol No.: 3098B1-203-WW)

AstraZeneca: A Multicenter, Randomized, Parallel-Group, Double-Blind, Phase III Comparison of the Efficacy and Safety of Quetiapine Fumarate (Oral Tablets 400mg to 800mg Daily in Divided Does) to Placebo When Used as Adjunct to Mood Stabilizers (Lithium or Valproate) in Maintenance Treatment of Bipolar I Disorder in Adult Patients (Protocol No.: D1447C00126)

AstraZeneca: A Multicenter, Double-Blind, Randomised –withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarte Sustained Release (SEROQUEL SR) as Monotherapy in the Maintenance Treatment of Patients with Major Depressive Disorder Following an Open-Label Stabilisation Period (AMETHYST STUDY) Protocol No.: D1448C00005

2004
Saegis Pharmaceuticals Inc.: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Efficacy and Safety of SGS742 in Subjects with Mild to Moderate Alzheimer’s Disease. (Protocol No.: SGS724-CL02) CRO: INC Research.

Ethica Clinical Research Inc.: A Double-Blind Comparison of BOTOX (Botulinum Toxin Type A) and TOPAMAX for the Prophylactic Treatment of Chronic Migraine Headaches – Pilot Study

2003
Allan Herskowitz, M.D., F.A.C.P.: Evaluation of BOTOX (Botulinum Toxin Type A) in the Treatment of Patients with Neck Pain (Single-Center, Randomized, Double-Blind, Two-Arm, Concurrent Placebo Control)

2002
Allan Herskowitz, M.D., F.A.C.P.: Evaluation of BOTOX (Botulinum Toxin Type A) in the Treatment of Patients with Subacute Low Back Pain (Single-Center, Randomized, Double-Blind, Two-Arm, Concurrent Placebo Control)

Sponsored Research Certifications
May 2017
Disability Assessment for Dementia (DAD) Clinical Rater Certification, i3 research for the Elan ELN115727-301/302 Alzheimer’s Disease Studies.

October 2009
Columbia-Suicide Severity Rating Scale (C-SSRS) Certification, Kelly Posner, Ph.D., Principal Investigator Center for Suicide Risk Assessment, Columbia University for the Sepracor 093-045 Partial Epilepsy Study.

October 2009
Montgomery-Asberg Depression Rating Scale (MADRS) Certification, ProPhase Training Group, Paul Michael Ramirez, Ph.D. and Mark G. Opler, Ph.D. for the Sepracor 093-045 Partial Epilepsy Study.

May 2008
Clinical Dementia Rating (CDR) Clinical Rater Certification, Washington University School of Medicine, Alzheimer’s Disease Research Center Memory & Aging Project for the Elan ELN115727-301-302 Alzheimer’s Disease Studies.

May 2005
Clinician’s Interview-Based Impression of Change (CIBIC) Certification, i3 research for the Fujisawa 03-0-189 Alzheimer’s Disease Studies.

Brad Herskowitz, MD is a neurologist located in Miami, Florida. You can contact his office at (305) 596-2080.